NCT06523231View on ClinicalTrials.gov

Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions
Shigellosis
Interventions
BIOLOGICAL

Shigella4V2

Adjuvanted Shigella4V2 administrated at 2 different doses: low and high.

BIOLOGICAL

MenACWY

Control vaccine

Trial Locations (1)

578,40100

KEMRI - Center for Global Health Research, Kisumu

Sponsors
All Listed Sponsors
collaborator

Kenya Medical Research Institute

OTHER

lead

LimmaTech Biologics AG

INDUSTRY